Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of Harvoni® (ledipasvir/sofosbuvir (LDV/SOF)
fixed-dose combination (FDC)) treatment under real world use in Japan. Among adult patients
with chronic genotype 1 hepatitis C virus (HCV) infection and treated with Harvoni in routine
clinical use, the primary objective of this study is to evaluate the incidence of adverse
drug reactions (ADRs) under real world settings.